.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Advances in the Treatment of Prostate Cancer

EP. 1: Advancements in Nonmetastatic CRPC

July 31st 2019

EP. 2: Imaging Utilized in Diagnosis of CRPC

July 31st 2019

EP. 3: MFS as a Clinical Endpoint in nmCRPC

July 31st 2019

EP. 4: Benefits of Newly Approved Drugs for M0 CRPC

July 31st 2019

EP. 5: Practical Advice on Follow-Up for Patients with M0 CRPC

July 31st 2019

EP. 6: Management of Adverse Events in M0 CRPC

July 31st 2019

EP. 7: Cardiac Toxicity in Nonmetastatic CRPC

July 31st 2019

EP. 8: Expanding Treatment Options for Metastatic CSPC

July 31st 2019

EP. 9: ASCO 2019: Novel Agents in Metastatic CSPC

July 31st 2019

EP. 10: Historical Perspectives on ADT in Prostate Cancer

July 31st 2019

EP. 11: Frontline Therapy in Newly Diagnosed Metastatic HSPC

July 31st 2019

EP. 12: AR-V7 as a Predictive Biomarker in Metastatic CRPC

July 31st 2019

EP. 13: Reducing Risk of Fracture in Metastatic CRPC

July 31st 2019

EP. 14: Patient Selection for Radium-223 in mCRPC

July 31st 2019

EP. 15: Sequencing in Nonmetastatic and Metastatic CRPC

July 31st 2019

EP. 16: Considerations for Genetic Testing in Prostate Cancer

July 31st 2019

EP. 17: Role of PARP Inhibitors in Prostate Cancer

July 31st 2019